您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > BAY 38-7271
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BAY 38-7271
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BAY 38-7271图片
CAS NO:212188-60-8
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
BAY38-7271是一个选择性、高效的大麻素受体CB1/CB2激动剂,对人重组CB1和CB2作用的Ki值分别为1.85nM和5.96nM。BAY38-7271具有很强的神经保护特性。
Cas No.212188-60-8
Canonical SMILESO=S(CCCC(F)(F)F)(OC1=CC=CC(OC2=CC=CC3=C2C[C@H](CO)C3)=C1)=O
分子式C20H21F3O5S
分子量430.44
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties[1].

BAY 38-7271 shows only minor interactions at the micromolar range with other binding sites such as adenosine A3 receptor (IC50 = 7.5 μM), peripheral GABAA benzodiazepine receptor (IC50 = 971 nM), melatonin ML1 receptor (IC50 = 3.3 μM), and at the monoamine transporter (IC50 = 1.7 μM)[1].

BAY 38-7271 (Ed50 = 0.02 mg/kg; i.v. and 0.5 mg/kg; i.p.) induces a potent and dose-de-pendent reduction in core body temperature[1].BAY 38-7271 has low physical dependence liability and is not essentially different from that of other cannabinoid CB1 receptor agonists[1].BAY 38-7271 (1-1000 ng/kg/h; i.v. infusion; for 4 hours) shows neuroprotective efficacy in the rat SDH model[1].BAY 38-7271 also has neuroprotective efficacy in models of transient and permanent occlusion of the middle cerebral artery and brain edema models[1]. Animal Model: Wistar rat ,TBI rat models (acute subdural hematoma, SDH)[1]

[1]. Mauler F, et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 2003 Winter;9(4):343-58.